 |
|
 |
|
|
MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs for the prevention and treatment of major medical diseases and certain conditions with unmet medical need. With its expertise and experience in product development, the Company is focused on advancing its pipeline of product candidates in the areas of infectious and degenerative diseases. MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. |
||
|
Fourth Quarter Fiscal 2008 Financial Results July 21, 2008
MIGENIX Fourth Quarter and Fiscal Year 2008 Financial Results Conference Call & Webcast July 21, 2008
Rodman & Renshaw 5th Annual Global HealthCare Conference May 19th - 20th, 2008 Click Here for Webcast Click Here for Presentation
Corporate Presentation BioFinance May 07, 2008 Click Here for Presentation
Third Quarter Fiscal 2008 Financial Results March 13, 2008
2007 Annual Report (PDF)
|
|
Monday, August 11, 2008(PDF) - MIGENIX Averts Proxy Contest; Reaches Agreement with DJohnson Holdings
Thursday, July 24, 2008(PDF) - Notice of MIGENIX General Meeting of Shareholders
Monday, July 21, 2008(PDF) - MIGENIX Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Friday, July 18, 2008(PDF) - MIGENIX Fourth Quarter and Fiscal Year 2008 Financial Results Conference Call & Webcast
Tuesday, July 8, 2008(PDF) - MIGENIX Corporate Update and Requisition of Special Meeting
Tuesday, May 27, 2008(PDF) - MIGENIX Takes Operational Actions to Extend Cash Past Upcoming Key Milestones
Tuesday, May 06, 2008(PDF) - Omigard™ Phase III Pivotal Registration Study Enrollment Completed
|
